20/20 Gene Systems Inc. is a Rockville, MD based manufacturer and developer
of unique tools for biomolecular analysis that use its proprietary layered
proteomics technology. 20/20's first product, the Multi-Replica Blotting
Kit for Protein is based on its unique Protein Function identification
Layered Membranes (P-Film a/k/a Film For Life). This product, released
in September 2001, allows biomedical researchers to analyze proteins with
substantial time and cost savings as compared to conventional methods.
20/20 Gene Systems has recently announced a distribution agreement with
Kodak for this product and expects to announce a separate distribution
arrangement for the product line for Japan and certain other Asian countries.
20/20 is also developing Image Analysis Software for use with the multi-replica
blotting kits. Also in development is a service for analysis of tissue
samples. More information may be obtained from 20/20's web page at 2020gene.com.
is an Owings Mills, Maryland advanced manufacturer of immuno detection
chemistries that include colorimetric and chemiluminescent formulations.
These include chemiluminescent substrates, ELISA products, immunohistochemicals,
diluents and coating solutions. It's products are noted for stability,
lot to lot consistency, and high signal to noise ratio. International
customers have achieved significant success with BioFx's TMB and AP Yellow
products, for example and like U.S. Customers have enjoyed BioFx' high
quality and reasonable prices. More about BioFx may be found at www.biofx.com.
Cary Pharmaceuticals is an
early stage pharmaceuticals development company located in Bethesda, Maryland.
Cary is developing Quitpak® an oral non-nicotine pharmaceutical product
designed for smoking cessation. Patents have been applied for in 26 countries,
and a U.S. Patent for Quitpak was issued in March, 2001. It is projected
that Quitpak will have an improved safety profile, improved cost effectiveness,
and an improved efficiency profile over existing treatments. Cary Pharmaceuticals
is also developing proprietary products for hypertension and for heartburn.
More about Cary Pharmaceuticals may be found at www.carypharm.com.
Inc. (CDI) is an early-stage medical device company headquartered in Bethesda,
Maryland. The Company is developing novel and proprietary whole blood diagnostic
assays to address unmet needs in the diagnosis and treatment of cardiovascular
disease. CDI's objective is to become the leading developer of whole blood
coagulation assays in the cardiovascular area.
CDI is developing products for assessing risk of a thrombotic event such
as a myocardial infarction (MI) or venous thrombosis, and for monitoring
of anticoagulant therapy. CDI has four products under development, which
are based on the tissue factor pathway. These are:
(i) the Tissue Factor Clotting Time (TiFaCT®) assay, a functional assay
that is used in the assessment of thrombotic risk,
(ii) the Tissue Factor Antibody (TiFAb) assay, which provides a rapid
assessment of the coagulation state,
(iii) the HepStat, which can monitor the effect of low molecular weight
heparin (LMWH) at the point-of-care, and
(iv) the ThromStat, an assay that clinicians can use to determine the active
clotting of patients, such as those presenting to emergency departments
with chest pain.
CDI's primary thrust is tissue factor, an inflammatory protein and the
primary initiator of blood coagulation under physiologic conditions. The
Company's technology platform offers several benefits:
(i) it focuses on the extrinsic pathway, the part of the coagulation cascade
that is most critical in vivo,
(ii) it produces functional assays that measure actual response as opposed
to predicted response,
(iii) it enables the targeting of specific coagulation factors, meaning
CDI can custom develop anticoagulant monitors for different drug mechanisms,
(iv) it is a promising link between thrombosis and heart attack.
CDI believes its assays can help emergency physicians assess the risk
of heart attacks rather than just identify damage after the fact. The
current state of medical practice for ruling in or ruling out MI has been
to use markers of necrosis or cell death. CDI's proprietary tissue factor
assays, however, would be used to predict an impending MI in the absence
of necrosis. CDI may be found on the web at www.coagdiag.com.
Cylex, is a Columbia,
Maryland based company that develops and markets tests and reagents for
clinical and research laboratories. The company has developed a patented
technology invitro CMT for performing immune function assessment
in the monitoring of AIDS patients, transplant recipients, cancer autoimmunity
and other infectious diseases. Cylex is currently selling Cylex test Kits
for research use applications and in the future will be making direct
sales to HIV, HCV, cancer and transplantation clinical and research laboratories.
Companies developing vaccines or immune based therapies are potential
partners for Cylex's technology. More information about Cylex may be obtained
Plantgenix, Inc. is
a Philadelphia, Pennsylvania development company that focuses on two vital
areas of plant activity: creating healthier, longer lasting plants or
creating natural factories. Plantgenix ethylene modulation technology
is a new approach to controlling ripening and aging in plants. By controlling
the response to ethylene, Plantgenix makes it possible to influence the
aging process in plants producing longer lasting flowers, fruits
and vegetables that ripen when desired. The first products commercially
available using this technology longer lasting garden plants with
more blooms are now being developed. In September, Plantgenix announced
a licensing agreement with Scotts Company, a world leading supplier of
lawn and garden care products, pertaining to new varieties of bedding
Plantgenix is the exclusive licensee of a number of key patents and technologies
developed by the University of Pennsylvania including a patent covering
new genetic technologies which facilitate the use of plants to produce
pharmaceutical and chemical compounds, detoxify contaminated soils, enhance
the nutritional value and health benefits of food and increase the resistance
of plants to herbicides. More information concerning Plantgenix and its
core technologies may be found at www.plantgenix.com.
Text Ore, Inc.
is an Arlington, Virginia based company that is commercializing a highly
advanced data mining technology. TextOre was originally developed for
the U.S. Intelligence Community by Litton TASC, a division of Litton Industries
that was acquired by Northrup Grumman Corporation.
TextOre can be used to mine any text, data or information that is in a
digital format. TextOre is easy to utilize and is unique in several important
features: a) it is multilingual and can data mine in any language (b)
it allows the user to rapidly determine what is relevant rather than have
a search engine establish it's own relevance rankings, (c) it is soon
to be available in several formats as a service, as an ASP model, as a
cutomized research tool, and on a subscription basis. More about TextOre
can be learned from www.textore.net
a Tysons Corner, Virginia based developer of authentication management
software for centrally managing user authentication, enabling organizations
to increase security, enhance user convenience and reduce cost. The BioNetrix
platform unifies authentication management, proving integrated support
for more than 20 advanced authentication methods including smart cards,
tokens and biometrics (fingerprints, face, iris, voice and signature recognition.)
Unlike any other solution available today, BioNetrix software enables
the implementation of context sensitive, strong authentication policies
to securely access client server, legacy and web-based applications.
BioNetrix has won numerous design and product awards that reflect the
state of the art nature of its security technology. It is rapidly gaining
customers in the financial, healthcare and commercial sectors. BioNetrix
is distributed in Japan by Netmarks, Inc. Trade Logistics & Strategies
was actively involved in the development of the Netmarks BioNetrix
relationship. BioNetrix may be found on the internet at www.bionetrix.com.
is an Arlington, Virginia technology company that provides business intelligence
and monitoring services for its clients based on its Netsapien technology.
Cyveillance provides expert customized solutions to enable businesses
to capture revenue by taking control of their brand identity, digital
assets and corporate reputation online. Cyveillance clients include companies
such as Merrill Lynch, DeBeers, Goodyear and Nintendo. Cyveillance solutions
pertain to such matters as brand protection, digital asset protection,
partner network and compliance, competitive and unauthorized distribution.
Additional information concerning Cyveillance may be found at www.cyveillance.com.
bigchalk, the digital learning source for education, harnesses the power
of online content to create engaging learning environments that promote
student achievement. Our state-of-the-art media and tools are valuable
resources for educators and their students.
- Library Resources, including
up-to-date online reference databases, facilitate student inquiry and
- Teacher Resources, including
easy-to-use tools for preparing lessons, help teachers motivate and
inspire their students.
- Online Curriculum, including
standards-based digital content for all levels, provides teachers with
the building blocks for classroom instruction.
At bigchalk, we know that
technology, used appropriately, can help today's learners achieve new
levels of knowledge and understanding.
bigchalk may be found on the internet at www.bigchalk.com